News
Robert F. Kennedy Jr. and I rarely see eye to eye, but I’ll grudgingly admit he’s not entirely wrong about food dyes, though ...
Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.
2d
Investor's Business Daily on MSNGardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...
Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...
Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...
Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...
United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results